Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Key facts

Study ID

NCT00052416

Run by

Beth Israel Deaconess Medical Center

Starts

2002-10-01

Expected to finish

2003-01-01

Last updated by the study team

2013-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Fletcher Allen Health Care - University Health Center Campus — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.